• American Fusion(TM) management participated in strategic meetings and forums in Washington, D.C., focused on energy security, resilient infrastructure, and military power requirements.
• The company recently completed the structural frame for a 5-megawatt Texatron(TM) pre-production unit, an important step toward integrated system assembly and testing.
• American Fusion(TM) describes Texatron(TM) as a “Fusion Engine(TM)” platform, reflecting a commercial infrastructure approach rather than a laboratory-focused research model.
• The company is advancing multiple corporate initiatives, including anticipated Form 10 effectiveness, Rule 15c2-11 quotation eligibility efforts and a Frankfurt quotation application.
• Management says its long-term strategy centers on modular fusion systems designed for scalable deployment across industrial, commercial and grid-constrained applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, is continuing to expand its presence within U.S. energy and defense discussions as the company advances development of its Texatron(TM) Fusion Engine(TM) platform. According to a recent company update, management participated in a series of strategic meetings and industry forums in Washington, D.C., where resilient energy infrastructure and long-term power security were recurring themes (https://ibn.fm/OdjZ8).

The meetings included engagements associated with the United States Energy Association and the Association of Defense Communities, organizations that frequently convene policymakers, infrastructure operators and defense-related stakeholders around issues tied to national energy resilience. During those discussions, American Fusion(TM) introduced aspects of its Texatron(TM) platform and its broader approach to compact fusion-based energy systems.

Management indicated that conversations centered on the long-term role advanced energy technologies could play in supporting defense installations, mission-critical infrastructure and distributed power systems. Executive Chairman Brent Nelson said one of the themes emerging from the discussions was the perception that the company’s technology is being viewed less as a conventional fusion research initiative and more as a practical energy platform aimed at infrastructure deployment.

“One of the recurring themes in Washington was that our technology is increasingly viewed less as a conventional fusion ‘science project’ and more as a practical energy platform. That distinction matters,” Nelson said. “Texatron(TM) is being developed as a Fusion Engine(TM) architecture designed around practical deployment, resilient power applications, and real-world infrastructure needs.”

That distinction is important for investors following the fusion sector. Much of the industry remains heavily focused on experimental validation and long-term scientific milestones. American Fusion(TM), by contrast, is attempting to position Texatron(TM) as a modular energy architecture designed around eventual commercial deployment and scalable infrastructure use cases.

The company recently announced completion of the structural frame for its 5-megawatt Texatron(TM) pre-production unit, which management describes as a key milestone ahead of integrated system assembly and controlled testing activities in Texas. The company is also continuing work related to diagnostics procurement, engineering integration and regulatory coordination.

While the company has reported successful plasma formation work using its proprietary pulsed torsatron design, the technology remains in development, but still focused on moving beyond scientific experimentation and toward engineering-driven commercialization strategies. American Fusion(TM) appears to be emphasizing that transition point in both its messaging and development roadmap. According to management, the company is currently pursuing multiple Texatron(TM) configurations, including a 5-megawatt demonstration-oriented system and a larger 100-megawatt design intended to support future commercial deployment concepts.

The modular structure of the company’s strategy is also notable. Management has described the architecture as scalable through standardized reactor units, allowing generation capacity to expand incrementally over time. In practical terms, multiple 100-megawatt systems could theoretically be combined into utility-scale generation infrastructure if the technology ultimately proves commercially viable.

The broader backdrop for these discussions is a growing focus on domestic energy resilience and infrastructure modernization. Rising electricity demand from data centers, industrial electrification and artificial intelligence computing workloads has renewed investor interest in next-generation baseload power technologies. Defense agencies and infrastructure planners have also increasingly discussed the strategic importance of resilient, distributed energy systems capable of operating independently from centralized grids.

American Fusion(TM) cautioned that participation in industry forums and stakeholder discussions does not constitute government endorsement or procurement activity. However, management stated that continued engagement with defense and energy policy communities remains an important part of positioning the Texatron(TM) platform within future infrastructure discussions.

Alongside technical development, the company is also advancing several capital markets initiatives. Management said it has submitted supporting documentation tied to an anticipated Rule 15c2-11 quotation application, which, if approved, could improve quotation visibility for the company’s shares.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Safe Pro Group Has Been Invited to a U.S. Army Force-on-Force (“FoF”) Combat Exercise designed to train and equip soldiers with its patented battlefield threat detection system.
• In the exercise, Safe Pro will showcase the system’s capabilities for rapidly identifying explosive threats combined with enhanced battlefield mapping.
• This invite follows Safe Pro’s recent participation in a U.S. Army active minefield exercise where the drone imagery analysis platform helped battlefield decision-making and operational planning in a live threat environment.

Safe Pro Group (NASDAQ: SPAI), a mission-driven tech company that develops security and defense solutions, recently revealed that it has been invited to participate in an upcoming U.S. Army FoF combat training exercise scheduled for the second quarter of 2026 (https://ibn.fm/JDs3f). FoF exercises are one of the Army’s most realistic combat training exercises, as they simulate live battlefield conditions between military units.

During these exercises, Safe Pro has been tasked with training and equipping soldiers with its NODE-X, AI edge imagery processing and mapping solution powered by its patented Safe Pro Object Threat Detection (“SPOTD”) technology. At the exercise, Safe Pro will highlight the system’s ability to use AI to rapidly identify explosive threats and produce enhanced battlefield maps.

This FoF opportunity comes after Safe Pro recently, and successfully, participated in a U.S. Army active minefield exercise where Safe Pro’s drone imagery analysis platform helped operational planning and battlefield decision-making in a live threat environment. During the exercise, Safe Pro’s NODE-X provided rapid battlefield intelligence and outcomes, helping commanders make important decisions that impacted mission success.

NODE-X is the next generation of Safe Pro’s AI-powered toolset that’s designed to offer battlefield intelligence at the tactical edge, by quickly analyzing drone imagery for both mapping and threat detection, right in the field without the need for cloud or internet connectivity.

The miniaturized NODE-X system is built for military operations and combines rapid threat detection, 3D terrain mapping, automated route planning, orthomosaic generation, and edge-based drone intelligence processing all in one compact platform.

The system is also backpack-sized, rugged, can integrate into various U.S. Army vehicles, and is even compatible with U.S. Army-approved Short-Range Reconnaissance (“SRR”) drones to deliver battlefield intelligence to soldiers and their commanders.

NODE-X, which is powered by the SPOTD technology, uses AI and machine learning algorithms which are trained on one of the largest real-world drone-based imagery datasets focused on detecting landmines and other unexploded ordnance (“UXO”).

In fact, the platform is capable of identifying more than 150 explosive threats and related objects. Safe Pro’s AI dataset also includes more than 2.75 million drone images and has over 50,000 confirmed detections of small threats.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that delivers AI-powered defense and security solutions, such as drone-based services and ballistic protective gear, to customers in a wide variety of industries. At the core of Safe Pro’s mission is computer vision software technology that rapidly detects and identifies small explosive threats in drone images and videos, to help enable safer field operations in conflict and post-conflict zones.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation.
• The company maintains royalty participation and equity ownership exposure to unbuzzd(TM) while preserving pharmaceutical and medical-use rights to related formulations.
• Lucid-MS has completed Phase 1 safety studies and advanced into the IND submission stage ahead of a planned Phase 2 clinical trial in multiple sclerosis.
• Quantum BioPharma’s portfolio spans both therapeutic drug development and consumer-focused wellness products, creating multiple potential operational and commercialization pathways.
• The company has reported sufficient working capital to sustain basic operations beyond January 2028 while continuing development across its pipeline and strategic initiatives.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company is advancing a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need.

The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.

The company is headquartered in Toronto, Ontario.

Portfolio

Lucid-MS

Lucid-MS (Lucid-21-302) is a patented new chemical entity being developed as a potential treatment for multiple sclerosis and other demyelinating diseases. The compound has demonstrated in preclinical models the ability to prevent and reverse myelin degradation while preserving neuronal health. According to the company, Lucid-MS is designed as a non-immunomodulatory, neuroprotective therapy targeting demyelination, a key driver of disease progression in multiple sclerosis.

Quantum BioPharma completed Phase 1 Single Ascending Dose (“SAD”) and Multiple Ascending Dose (“MAD”) studies evaluating the safety and tolerability of Lucid-MS in healthy volunteers. The company submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration in March 2026 to support a planned Phase 2 clinical trial in multiple sclerosis patients. The focus of the study is intended to be in patients suffering from PPMS (primary progressive) and SPMS (secondary progressive) types of the disease. Quantum BioPharma has also entered into a binding letter of intent with global clinical research organization Allucent to support the planned Phase 2 study.

Lucid-MS has been studied through more than a decade of research and development and has shown efficacy in several preclinical animal models. Quantum BioPharma maintains exclusive worldwide rights to the compound through its wholly owned subsidiary, Lucid Psycheceuticals Inc.

unbuzzd(TM) and REKVRY(TM)

Quantum BioPharma developed unbuzzd(TM), a dietary supplement beverage formulation designed to accelerate alcohol metabolism, reduce blood alcohol concentration and improve mental alertness following alcohol consumption. The company spun out the over-the-counter consumer version of the product to Unbuzzd Wellness Inc., formerly Celly Nutrition Corp., while retaining an ownership stake and royalty participation. Under the agreement, Quantum BioPharma retains a 7% royalty on sales of unbuzzd(TM) until aggregate payments reach $250 million, after which the royalty decreases to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.

In March 2026, results from a double-blind, randomized, placebo-controlled crossover clinical trial investigating unbuzzd(TM) were published in a peer-reviewed scientific journal. According to the company, the study demonstrated statistically significant improvements in alcohol metabolism, reductions in blood alcohol concentration, improved alertness and reduced hangover symptoms compared to placebo.

Quantum BioPharma is also developing REKVRY(TM), a formulation intended for alcohol misuse treatment in hospital and emergency settings, which the company believes may help address healthcare burden associated with alcohol intoxication and misuse.

Market Opportunity

Quantum BioPharma is targeting large global markets across multiple sclerosis treatment, alcohol recovery products and functional wellness beverages. According to company materials, approximately 2.8 million people worldwide are living with multiple sclerosis, including nearly one million people in the United States alone. The company has cited projections indicating the global multiple sclerosis market could grow from approximately $28.2 billion in 2022 to approximately $41 billion by 2033.

The company is also targeting the growing hangover recovery and alcohol wellness market through unbuzzd(TM). According to Quantum BioPharma’s materials, the global hangover cure products market was valued at approximately $2.05 billion in 2022 and is projected to reach approximately $6.2 billion by 2030, representing a compound annual growth rate of 14.8%. Quantum BioPharma has additionally cited estimates that excessive alcohol consumption costs the United States approximately $249 billion annually through healthcare costs, lost productivity, criminal justice impacts, vehicle crashes and property damage. The company has also referenced projections estimating the broader functional beverage market could reach approximately $198 billion in 2026.

Leadership Team

Zeeshan Saeed, Founder, CEO, President & Executive Co-Chair, founded Quantum BioPharma and played a key role in securing the company’s initial seed capital and transition into a publicly traded company. Prior to founding Quantum BioPharma, he served as President of ZZ Telecommunications Inc., a long-distance telecommunications carrier, and previously founded Platinum Telecommunications Inc. Mr. Saeed has experience in international capital markets, including assisting startups with raising capital and securing exchange listings, and holds a Bachelor of Science in Mechanical Engineering.

Anthony Durkacz, Co-Founder & Executive Co-Chair and previously served as President of Capital Ideas Investor Relations, was the CFO and a director of Snipp Interactive, as well as was COO and CFO of MKU Canada and Astris Energi.

Donal Carroll, CPA, CFO & COO, has more than 20 years of corporate finance leadership and public company experience. Prior to joining Quantum BioPharma, he served as Country CFO with Videojet Technologies, a Danaher company, Accounting Supervisor with Alberto Culver, now part of Unilever, and Corporate Controller with Cardinal Meats.

Jason Sawyer, Head of Finance and M&A, is a veteran financier who has led Bahamas-based alternative investment and advisory firm Access Alternative Group S.A. for more than 20 years. According to the company, AAG and its affiliates have completed more than $5 billion in capital placements involving alternative fund managers, private and public startups, early-stage growth companies and targeted mergers and acquisitions across multiple sectors. Mr. Sawyer also serves on various corporate boards and advisory committees.

Lakshmi P. Kotra, PhD, President of Quantum BioPharma and CEO of Quantum BioPharma Australia Pty Ltd., is a Senior Scientist at the Krembil Brain Institute within University Health Network and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra joined Quantum BioPharma in connection with the acquisition of Lucid Psycheceuticals in 2021 and is the recipient of the Julia Levy Award for contributions to the commercialization of biomedical innovation in Canada. His background includes research and development work involving anti-HIV drugs, antibacterials, insulin, antimalarials, medical cannabis therapeutics and treatments targeting multiple sclerosis.

Andrzej Chruscinski, MD, PhD, Vice-President, Clinical and Scientific Affairs, leads Quantum BioPharma’s clinical programs and clinical trial activities. Dr. Chruscinski received his MD and PhD from Stanford University, completed residency training in internal medicine at Stanford and fellowships in cardiology at Stanford and Toronto General Hospital. He has led major clinical trials involving transplantation tolerance and biomarker discovery and is a board-certified cardiologist.

Eric Hoskins, MD, DPhil, Director, is a physician and public health expert with more than 30 years of experience spanning healthcare, public policy, economic development and international trade. Dr. Hoskins previously served as Ontario’s Minister of Health and Long-Term Care and held several additional cabinet positions during nearly a decade as a member of provincial parliament. He also served as president of War Child Canada and was awarded the Order of Canada in 2007 for his humanitarian work.

For more information, visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• Earth Science Tech has positioned itself as a diversified healthcare holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation.
• The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams.
• Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value.
• The growing company operates multiple subsidiaries spanning compounding pharmacies, telehealth platforms, clinics, healthcare support services, real estate and cash management.

Over the past several years, Earth Science Tech (OTC: ETST), a strategic holding company, has undergone a significant transformation. Divesting legacy wellness operations, the company has repositioned itself to acquire and scale cash-flowing assets across healthcare, pharmaceutical compounding and telemedicine, alongside active cash management, through a growing network of subsidiaries operating under the umbrella of a diversified holding company structure.

Today, the company executes a strategy focused on acquiring and actively managing businesses capable of generating sustainable long-term cash flow across regulated healthcare, real estate, cash management, and related industries. That transition became more visible in March when Earth Science Tech announced the formal launch of MyOnlineConsultation.com through MOCTeledoc LLC, a telehealth division designed to provide integrated physician networks, technology infrastructure and clinical staffing services (https://ibn.fm/cAxV7).

The launch marked the completion of what management calls a vertically integrated healthcare ecosystem linking telemedicine consultations directly with the company’s pharmacy operations.

According to the company, MOCTeledoc completed its beta phase as a cash-flow-positive operation, an outcome management cited as validation of the division’s lean, high margin operating structure. The telehealth platform now connects directly with Earth Science Tech’s wholly owned compounding pharmacy subsidiaries, including RxCompoundStore.com and Mister Meds, while also maintaining flexibility to route prescriptions to external pharmacy partners when appropriate.

By internalizing the patient journey from front-end consultation to back-end prescription fulfillment, Earth Science Tech captures margin across the entire care continuum. In this model, telemedicine services often function as a low-friction customer acquisition channel for patients seeking consultations, customized medications or ongoing healthcare management. Compounding pharmacies, meanwhile, can generate high-retention, repeat prescription activity over extended periods. By linking the two operationally, Earth Science Tech optimizes customer lifetime value (“LTV”), creating a healthcare ecosystem where patient engagement, prescription fulfilment and clinical support reinforce one another internally.

The company’s healthcare operations are now spread across multiple subsidiaries.

RxCompoundStore.com, a licensed compounding pharmacy based in Florida, and Mister Meds based in Texas, are authorized to fulfil prescriptions across more than 33 U.S. states and Puerto Rico, with additional licensing expansion underway. Additional healthcare exposure comes through Peaks Curative, DOConsultations, and Las Villas Health Care, which together support telemedicine consultations, customized medication delivery, and specialized healthcare services including outreach to Spanish-speaking patient communities.

Outside healthcare, Earth Science Tech mitigates risk and builds tangible equity through Avenvi, its dedicated property development and cash management division. Avenvi serves as a vital pillar in the company’s broader strategy to generate non-correlated revenue streams and build hard asset value. The division manages its physical property developments and its real estate assets currently include multiple lots, one developed residential property, and the one standalone commercial property. Highlighting the operational synergies within Earth Science Tech’s holding structure, this commercial building serves as the physical operating facility for the company’s Mister Meds pharmacy subsidiary. By combining disciplined cash management with tangible real estate assets, Avenvi balances the high-growth nature of the healthcare subsidiaries with stable, alternative asset classes, anchoring the balance sheet and ensuring the holding company is not solely reliant on the medical sector, providing a durable foundation for long-term equity growth.

That diversified structure reflects the company’s broader holding company approach, leveraging assets and cash flows from multiple sectors. Importantly, management has also actively distinguished the company through rigorous capital allocation and shareholder-focused initiatives. 

One area that has drawn attention among investors is Earth Science Tech’s ongoing share repurchase activity. Unlike micro-cap peers reliant on dilutive financing, ETST utilizes free cash flow to systematically execute buybacks. This continuously reduces the number of publicly traded shares outstanding, directly mitigating dilution while signaling management confidence in long-term operating performance and fundamental value. The company has indicated that share retirement initiatives are expected to continue as part of its broader capital management strategy.

For micro-and small-cap public companies, disciplined capital allocation carries particular significance. Investors often scrutinize dilution risk closely, especially among emerging growth businesses operating in capital-intensive sectors. Earth Science Tech’s emphasis on stock buybacks, tangible asset growth through Avenvi, and self-funded scaling directly addresses those concerns while reinforcing strict balance-sheet discipline.

The company has also worked to strengthen its regulatory positioning, operating under SIC 2834 pharmaceutical classification standards and has securing FINRA Form 211 clearance, measures that improve transparency and market credibility among institutional and retail investors evaluating OTC-listed healthcare companies. 

The macroeconomic market backdrop supports ETST’s continued growth opportunities across expanding total addressable markets (“TAM”). The pharmaceutical compounding industry has expanded steadily as demand rises for personalized medications, dosage customization and flexible supply alternatives. Industry research cited by the company estimates the global compounding pharmacy market was valued at approximately US$13.1 billion in 2023 and could reach US$18.6 billion by 2030.

Telemedicine growth has been even more pronounced. Forecasts referenced by the company project the global telemedicine market could expand from approximately US$112 billion in 2025 to more than US$530 billion by 2034 as digital healthcare adoption accelerates. North America remains the largest regional telemedicine market.

Earth Science Tech’s integrated operating model to position the company at the intersection of diverse secular economic trends: scalable digital healthcare delivery, high-margin pharmaceutical fulfilment, and tangible asset accumulation through real estate and disciplined cash management. The company’s combination of recurring pharmacy revenue, telemedicine infrastructure, Avenvi’s active cash management and property holdings, and shareholder-focused capital management, distinguishes it from speculative, cash-burning early-stage healthcare companies operating in fragmented digital health markets.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax Minerals is expanding its North American rare earth element exploration portfolio across Canada and the United States to address the significant dependence on China for processed rare earth materials supporting key defense and industrial applications.
• China controls roughly 60% of global rare earth mining and approximately 90% of downstream processing capacity.
• Growing Pentagon demand for drones, missile systems, and advanced electronics, continues to ratchet up demand for secure non-Chinese rare earth supply chains.
• Powermax recently moved to acquire the Hopkins Rare Earths Project in northern Ontario, adding to projects in British Columbia, Ontario, and Wyoming.
  

As the United States accelerates efforts to rebuild domestic supply chains for critical minerals, exploration companies focused on rare earth elements are attracting growing investor attention. Among them is Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America. The company is assembling a portfolio of important rare earth element (“REE”) projects in North America at a time when geopolitical concerns and defense requirements are reshaping how governments approach strategic mineral supply.

Rare earth elements are essential to a broad range of modern technologies, including electric vehicles, wind turbines, advanced electronics, military guidance systems, jet engines, and permanent magnets. The growing demand must be met with increased mining as well as economical processing and refining.

Industry estimates indicate China controls approximately 60% of global rare earth mining and roughly 90% of downstream processing capacity. Beijing has also imposed export restrictions and licensing requirements on several heavy rare earth elements and related technologies, raising concerns in Washington and among allied governments about long-term supply security.

The issue has become particularly urgent for the U.S. defense sector. A recent report highlighted that the Pentagon has ordered tens of thousands of one-way attack drones, with plans to scale production beyond 300,000 units by early 2028. Each drone depends on rare earth magnets, while roughly 98% of global magnet manufacturing remains centered in China (https://ibn.fm/vi2bb).

According to the same report, more than 80,000 components across approximately 1,900 U.S. weapons systems rely on Chinese rare earth materials or components. These include drone motors, missile guidance systems, sensors and aerospace applications.

The distinction between light and heavy rare earth elements is becoming increasingly important in strategic planning. Light rare earths such as neodymium and praseodymium are commonly used in permanent magnets for electric vehicles and electronics. Heavy rare earths including dysprosium and terbium play a critical role in maintaining magnet performance under high temperatures and harsh operating conditions typical of military systems and aerospace applications.

Western governments are now attempting to reduce that dependency. The U.S. Department of Defense and other federal agencies have directed substantial funding toward rare earth development through government instruments including the Defense Production Act. The Pentagon’s investment activity has included equity participation and financing commitments designed to support domestic and allied supply chains.

At the same time, industry analysts caution that developing alternative processing capacity is a long-term undertaking. Building mines may take several years, but establishing metallurgical expertise, refining capability and qualified downstream manufacturing systems can require considerably longer.

That broader backdrop has helped increase interest in companies such as Powermax Minerals as a potentially critical component in the supply chain. The company’s portfolio includes the Cameron REE property in British Columbia, the Atikokan and Pinard projects in Ontario, and the Ogden Bear Lodge Project in Wyoming. 

Recently, Powermax also announced an option agreement to acquire a 100% interest in the Hopkins Rare Earths Project in northern Ontario. The Hopkins property covers approximately 5,900 hectares within the Clay-Howells Alkalic Rock Complex, a geological setting associated with rare earth exploration activity. Planned exploration work includes airborne geophysics, radiometric surveys, geological mapping and geochemical sampling. Management says the acquisition is intended to strengthen the company’s growing North American REE portfolio and increase exposure to jurisdictions viewed as geopolitically stable.

These developments come as global demand for rare earth elements is projected to rise sharply over the coming decade, driven by electrification, renewable energy deployment, artificial intelligence infrastructure, robotics and military modernization. Industry forecasts cited by the company suggest global REE demand could triple from approximately 59,000 tonnes in 2022 to roughly 176,000 tonnes by 2035.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, is optimistic about historically high gold prices
• With the ongoing global political issues, there has been oil-driven inflation and a general lack of faith in traditional stores of wealth, which experts note are long-term drivers of gold prices
• ESGold has positioned itself to take advantage of this growth, being fully funded to execute, and is on track to kicking off production at its flagship Montauban Gold-Silver Project in Quebec
• Gordon Robb, ESGold’s CEO, has noted that 2026 will be a major year for the company, with important milestones being achieved, and with ongoing market factors in their favor

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, remains optimistic about gold prices in 2026 and is positioning itself to take advantage of it. This comes amid growing oil-driven inflation and debt factors which continues to highlight gold as a safety hedge, both for the short-term and long-term (https://ibn.fm/BGLjF).

As of May 21, 2026, the price of gold was trading at $4,504 an ounce, up from $3,312 a year ago. According to JPMorgan, it is projected that by year-end, this price will likely hit close to $6,000 per troy ounce, a key signal pointing to the potential gold has for growth and its viability as an important hedge investment vehicle (https://ibn.fm/waijw).

The ongoing global issue as well as the high price of crude oil are key to shaping this outcome as time progresses. Higher oil prices have increased inflation risks, all while increasing chances of higher-for-longer interest rates. Regardless, ESGold believes there is still value in gold as a hedge against this inflation and looks to capitalize on its anticipated uptake.

“Given the current high negative correlation to oil, dollar, and yields, these – especially oil – will set the tone for gold in the upcoming sessions,” noted Ole Hansen, head of commodity strategy at Saxo Bank (https://ibn.fm/BGLjF).

Back in the 1970s, high inflation, paired with weak economic growth, led to massive gains in gold. Between 1976 and 1080, the price of a troy ounce grew from $125 to $859. The pattern was further replicated in the 2020s, when there was a global inflationary spike, with gold serving as a crucial defensive asset, which led to its price rising. Experts point out that the pattern might repeat itself this year as well, with the ongoing global political climate and the oil-induced inflation. As a result, ESGold is positioning itself to capitalize on the spike in demand and the accompanying surge in gold prices.

Thus far, the company has positioned itself for growth and set itself up for success. It is fully funded to execute and is on track to kick off production at its flagship Montauban Gold-Silver Project in Quebec. Earlier this month, it expanded its Montauban footprint with a 2,448-hectare strategic claim and bolstered its senior leadership, with Jason Tong as its new Chief Financial Officer (“CFO”). Gordon Robb, the company’s CEO, has reiterated that 2026 will be a big year 2026 will be for ESGold, and the steps taken so far, the milestones achieved, and the current state of the world, it is safe to say that the company is on track to have its best year yet.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows.
• Clinical data show ~100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage.
• A single ~10-minute procedure with ~2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients.
• The product targets an estimated ~$3 billion U.S. market with ~470,000 annual cases and no comparable ready-to-use competitor.
• Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the company is approaching key catalysts including commercialization and FDA submission.

Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair—no cells, no delays, no complexity. Its GelrinC(R) platform delivers faster recovery, stronger outcomes, and lower costs vs. outdated procedures, with clinical data showing ~100% greater pain improvement vs. microfracture. Already CE Mark approved in Europe and advancing through a pivotal U.S. Phase III trial, Regentis is stacked with near-term catalysts that could redefine orthopedic care—and unlock massive upside.

Company Overview

Regentis is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on knee injuries and other orthopedic treatments, Regentis’ Gelrin(TM) platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate durable and healthy cartilage in a controlled and synchronous process with sustained results. GelrinC(R) aims to address an estimated $3 billion annual U.S. market of approximately 470,000 cases of knee cartilage repair, where no off-the-shelf treatment is available. It has CE Mark approval for commercialization in Europe and has completed more than 50% enrollment in its pivotal Phase III study for U.S. FDA approval. Several upcoming value-driving catalysts include completion of the U.S. pivotal trial, commercialization in Europe, and submission for FDA approval in the U.S.

Investment Highlights

Positioned as a First-in-Class Off-the-Shelf Solution for Knee Cartilage Repair in the U.S.

GelrinC(R) is built to disrupt a broken standard of care. A true single-step, off-the-shelf implant, it eliminates cell harvesting, lab delays, and multi-stage surgeries. While legacy treatments are either ineffective or overly complex, GelrinC(R) delivers a fast, ~10-minute procedure that fits seamlessly into existing workflows. This is a category-defining product with the potential to displace both microfracture and expensive cell-based therapies.

Compelling Clinical Efficacy That Outperforms Legacy Treatments

GelrinC(R) isn’t just simpler—it’s clinically superior. Data shows ~100% greater improvement in pain scores vs. microfracture at two years, with durable, multi-year outcomes and no adverse events to date. MRI results confirm near-complete cartilage regeneration, the gold standard in the field. This is the rare combination investors look for: clear, measurable superiority with lasting results.

Stronger Economics That Accelerate Adoption

GelrinC(R) aligns with how healthcare actually works: faster, cheaper, and easier. A single minimally invasive procedure, ~2-week recovery (vs. ~6 weeks), and significantly lower costs than $40K+ cell therapies create a powerful value proposition. The result: high-margin scalability with strong incentives for surgeons, payers, and patients alike.

Large, Underpenetrated Market with Clear Catalysts Ahead

Targeting a ~$3B U.S. market with ~470K annual cases, GelrinC(R) is entering a space with massive unmet demand and no true off-the-shelf competitor. With CE Mark approval already secured in Europe and a U.S. pivotal trial over 50% enrolled, Regentis is approaching major value inflection points—including trial completion, FDA submission, and commercialization. This is a high-upside, catalyst-rich story investors can’t ignore.

Leadership Team

Ehud Geller, PhD, MBA, Chief Executive Officer and Executive Chairman, brings extensive leadership experience in the pharmaceutical and biotechnology industries, having previously served as President and CEO of Interpharm Laboratories and as an executive vice president at Teva Group, along with leadership roles in industry organizations and public markets.

Galit Reske, PhD, Chief Medical Officer, has significant expertise in clinical development and regulatory strategy, including leading roles in global clinical operations and contributing to the FDA approval of the cartilage repair product Agili-C, which was later acquired by Smith+Nephew in a $330 million transaction.

Ori Gon, CPA, Chief Financial Officer and Chief Business Officer, has more than 15 years of financial leadership experience across public and private companies and has led multiple capital raises totaling over $150 million.

Nadya Lisovoder, MD, Director of Clinical Operations, has broad experience managing clinical studies across multiple geographies and therapeutic areas, overseeing programs from early-stage development through regulatory submission in the United States, Europe, Israel, and Australia.

For more information, visit the company’s website at https://www.regentis.co.il.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Two of the Web3 community’s most recognized programming tracks rejoin Canada’s flagship event, bringing dedicated developer and women-focused experiences to Rebel Entertainment Complex this July

Blockchain Futurist Conference is pleased to confirm that both ETHWomen and ETHToronto will once again be featured as part of the 2026 Toronto programme, taking place July 21–22 at Rebel Entertainment Complex and Cabana Pool Bar.

Now in its fifth annual edition, ETHToronto returns on July 22 as the Web3 developer experience at Blockchain Futurist Conference. Organized by the team behind some of Canada’s longest-running crypto events since 2013, ETHToronto brings together builders, hackers, developers, and innovators from across Ethereum and the broader Web3 ecosystem. ETHToronto 2026 is proudly sponsored byAutheo. The event is free to register and open to all conference attendees, running as a dedicated programming track within the Futurist venue. Registration is available at www.ethtoronto.ca.

ETHWomen returns across both conference days, July 21–22, as a dynamic and community-driven experience dedicated to connecting, celebrating, and advancing women in the Web3 and blockchain space. Now an established fixture within Blockchain Futurist Conference, ETHWomen has grown into a global initiative that convenes hundreds of women through sessions focused on networking, collaboration, and learning. This year’s programming will also feature a breakfast sponsored by SheFi and a facilitated networking session sponsored by Women in Crypto. Free passes are available and tickets are limited, so those interested are encouraged to register early at www.ethwomen.com.

Confirmed ETHWomen 2026 speakers include Staci Warden, CEO of the Algorand Foundation; Ada Vaughan, Senior Director of DeFi Partnerships at the Stellar Development Foundation; Janet Adams, Board Member of the Artificial Superintelligence Alliance and COO of SingularityNet; Jaime Leverton, CEO of ReserveOne; and Lisa Loud, Executive Director of Secret Network. Additional speakers will be announced in the weeks ahead.

Both ETHWomen and ETHToronto are included with the purchase of a General Pass to Blockchain Futurist Conference Toronto 2026, reinforcing the conference’s commitment to providing a multi-layered, high-value experience across the full two days. Together with the AI Futurist Conference, Beginner Bootcamps, and the broader Canada Crypto Week side event programming, they reflect Futurist’s ongoing investment in building an event ecosystem rather than a single-day show.

ETHWomen will also make its return in the United States alongside the Florida edition of Blockchain Futurist Conference, with dates set for November 17–18, 2026.

Conference Tickets (includes ETHWomen & ETHToronto): futuristconference.com/toronto/ticket

ETHWomen Sponsorships: ethwomen.com/sponsorship-form

ETHToronto Registration (Free): www.ethtoronto.ca

ETHWomen Registration (Free): www.ethwomen.com

For media passes or media inquiries, please contact james@futuristconference.com

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• AI-powered security and defense solutions company Safe Pro Group recently released its financial results for the quarter ending March 31, 2026, showing a 560% quarterly revenue increase, driven by 2,400% growth in its high margin AI revenue, and a strong balance sheet.
• In addition to finances, Safe Pro also revealed some operational highlights, such as delivering Edge processing systems to the U.S. Government, offering support for Edge processing, an expanded leadership team, and a growing interest in its solutions.
• Safe Pro also launched a new growth team, led by Brian Mack as Chief Growth Officer and Benjamin Chitty, VP of Government Growth, which will lead its efforts to capture U.S. government contract awards through teaming agreements with Prime Contractors.

Safe Pro Group (NASDAQ: SPAI), a tech company that delivers AI-powered security and defense solutions, recently revealed its financial results for the quarter ending March 31, 2026 (https://ibn.fm/RLuo5). The highlights showed significant growth driven by the sales of its AI products.

Safe Pro Group’s quarterly revenue rose to over $1,220,129, up from the $184,8092 reported in the first quarter of 2025. This represents a 560% increase. Safe Pro AI quarterly revenue jumped over 2,400%, largely driven by new contracted sales of its AI-powered and drone-based video and image analysis systems.

Safe Pro’s quarterly consolidated gross margins were more than 68% inclusive of deprecation, validating its scalable business model. At the end of the quarter, Safe Pro supported a strong balance sheet with $14.8 million in cash and only minimal debt.

The company also covered important operational results from the quarter.

This includes Safe Pro delivering multiple Edge processing systems under a $1,000,000 government contract, as well as a contract modification that expanded this to also include providing support for these Edge processing systems.

The interest in Safe Pro’s Navigation, Observation & Detection Engine (“NODE”), and the new NODE-X miniaturized Edge processing solution, continues to grow following several live demonstrations and exercises conducted by the U.S. Army. By participating in these events, Safe Pro has the opportunity to directly engage with decision-makers in the defense industry who may be able to offer a path to product acquisition and deployment.

The company has also expanded its leadership team, and launched a new Growth Team (https://ibn.fm/AQtOI). The team is led by Brian Mack as the Chief Growth Officer and Benjamin Chitty as the VP of Government Growth. This group is leading Safe Pro’s efforts to get more U.S. government awards via teaming agreements with Prime Contractors.

Speaking about these results and the future of Safe Pro, the Chairman and CEO of Safe Pro Group, Dan Erdberg, said that “We believe Safe Pro is well positioned to capitalize on the AI era with the momentum we see building for our patented AI solutions within the U.S. Government. Supported by a strong balance sheet, expanded team of accomplished military acquisition specialists, and an enhanced portfolio of real-world proven solutions, we are excited about our future.”

About Safe Pro Group Inc.

Safe Pro Group is a mission-driven tech company that delivers advanced and AI-powered security and defense solutions to industries like law enforcement, humanitarian, homeland security, and defense. It offers drone-based services and ballistic protective gear, and the core of Safe Pro’s offering is its patented computer vision software technology that can rapidly detect small objects in drone-based videos and images, to enable more efficient and safe field operations.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

• Near-term gold producer LaFleur Minerals is reporting new assay results from infill diamond core drilling that bolster expectations that mineralization remains open at depth and along strike in the company’s Swanson Gold Deposit
• The findings follow up on the mineral resource estimate completed earlier this year with the potential for additional high-grade shoots within the system and broader zones of gold mineralization
• LaFleur’s nearly 22,400-hectare Swanson and McKenzie East gold projects are located within the prolific Abitibi Greenstone Belt of eastern Canada, within the Val-d’Or mining camp where labor and supply resources are centralized for mining operations in the region

Infill diamond-core drilling continues to yield a path to the potential expansion of resources in the Abitibi Greenstone Belt-situated Swanson Gold Deposit owned and operated by near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF).

The company’s flagship property in Eastern Canada’s prolific gold mining district — one of the largest gold belts in the world — combined with the recently acquired McKenzie East Gold Project nearby, covers more than 450 exploration mining claims that are located on nearly 22,400 hectares (about 55,350 acres).

LaFleur’s May 12 news release provides an outline of significant assay results from the company’s ongoing drilling program at its Swanson Gold Deposit, highlighting findings of 2.95 g/t Au over 80.00 meters, 2.37 g/t Au over 88.05 meters, 1.29 g/t Au over 93.85 meters, and 0.86 g/t Au over 103.55 meters plus 1.14 g/t Au over 56.65 meters in four of the seven newly reported drill holes (https://ibn.fm/FcTIO).

The assays have increased confidence that continuity of mineralization exists both within and beyond LaFleur’s proposed pit shell at depth, enhancing the mineral resource estimate completed just a few months ago with the potential for high-grade shoots within the system at depth.

The drill program focused on previously untested depths where spacing between historical drill holes exceeded 50 meters, establishing higher grade sub-intervals, such as 232.00 g/t Au over 0.50 meters, 3.98 g/t Au over 9.00 meters and 7.78 g/t Au over 1.90 meters between two of the holes and leaving mineralization open at depth and along strike.

Visible gold was encountered in three of the seven recently drilled holes. 

“LaFleur has intersected some of the strongest and widest gold mineralization to date at its Swanson Gold Project, indicating the presence of broad zones of gold mineralization extending beyond the limits of the current open pit resource at the Swanson Gold Deposit and highlighting the emergence of a potentially much larger, high-growth gold system with compelling expansion potential,” LaFleur Chairman Kal Malhi stated.

Swanson is located in the Val-d’Or mining district — an established central hub for labor and other resources that support mineral exploration activities in the Abitibi. The company completed a Preliminary Economic Assessment (“PEA”) in March that anticipates a strong economic return from the project and the company’s nearby Beacon Gold Mill, which is expected to resume gold production operations during the next quarter.

LaFleur is building its profitability forecast on a base case price closer to where gold traded in January 2025 instead of current levels, meaning that the metal’s price remains far above the level LaFleur sees as the foundation for its strategy. The gold market has since achieved historic highs as it more than doubled value after January 2025, and the precious metal continues to trade at lofty levels despite recent price fluctuations that have sometimes challenged the expectations of investors (https://ibn.fm/luwBz).

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.